Drugs /

famotidine

Back to Drugs List

Overview

NCI Definition [1]:
A propanimidamide and histamine H2-receptor antagonist with antacid activity. As a competitive inhibitor of histamine H2-receptors located on the basolateral membrane of the parietal cell, famotidine reduces basal and nocturnal gastric acid secretion, resulting in a reduction in gastric volume, acidity, and amount of gastric acid released in response to various stimuli.

Clinical Trials

View Clinical Trials for famotidine

Famotidine has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating famotidine, 1 is phase 2 (1 open).

CDKN2A Overexpression and HPV Positive are the most frequent biomarker inclusion criteria for famotidine clinical trials.

Head and neck squamous cell carcinoma and oropharyngeal squamous cell carcinoma are the most common diseases being investigated in famotidine clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Famotidine
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating famotidine and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
famotidine [chemical/ingredient], famotidinum, propanimidamide, 3-(((2-((aminoiminomethyl)amino)-4-thiazolyl)methyl)thio)-n-(aminosulfonyl)-, famotidine (product), pepcid, 3-(((2-((diaminomethylene)amino)-4-thiazolyl)methyl)thio)-n(sup 2)-sulfamoylpropionamidine, 3-(((2-((aminoiminomethyl)amino)-4-thiazolyl)methyl)thio)-n-(aminosulfonyl)propanimidamide, pepcid ac, (1-amino-3-(((2-((diaminomethylene)amino)-4-thiazolyl)methyl)thio)propylidene)sulfamide, famotidine (substance), famotidine, n-sulfamoyl-3-((2-guanidinothiazol-4-yl)methylthio)propionamide, famotidine, famotidina, 76824-35-6
NCIT ID [1]:
C29045
SNOMED ID [1]:
C-84020

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.